Docivyx Injection, Solution
NDC 83831-102
Product Information
Docivyx (docetaxel) is a NDA-approved product labeled by Avyxa Pharma, Llc. This medication is used to treat cancer (such as breast, lung, prostate, stomach, and head/neck cancer). It is supplied as a injection, solution for intravenous administration. This product entry covers the primary NDC 83831-102 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 83831-102?
What are the uses of this product?
What are Active Ingredients of this product?
- DOCETAXEL 80 mg/8mL - A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DOCETAXEL (UNII: 15H5577CQD)
- DOCETAXEL ANHYDROUS (UNII: 699121PHCA) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POLYETHYLENE GLYCOL 300 (UNII: 5655G9Y8AQ)
- POVIDONE (UNII: FZ989GH94E)
- ALCOHOL (UNII: 3K9958V90M)
- BETADEX SULFOBUTYL ETHER SODIUM (UNII: 2PP9364507)
- ANHYDROUS CITRIC ACID (UNII: XF417D3PSL)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1860619 - DOCEtaxel 20 MG in 2 ML Injection
- RxCUI: 1860619 - 2 ML docetaxel 10 MG/ML Injection
- RxCUI: 1860619 - docetaxel 20 MG per 2 ML Injection
- RxCUI: 2679779 - DOCEtaxel 160 MG in 16 ML Injection
- RxCUI: 2679779 - 16 ML docetaxel 10 MG/ML Injection
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.